Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf [Yahoo! Finance]
Protara Therapeutics, Inc. (TARA)
Company Research
Source: Yahoo! Finance
33% at 12 months (n=15), which management attributes to small-sample volatility and expects to rise toward ~40% as the study enrolls to a planned 100 patients; the company is pursuing ADVANCED-3 , a front-line randomized trial intended to position TARA-002 as an alternative when BCG is unavailable or inappropriate. STARBORN-1 (lymphatic malformations) : Enrollment is ongoing and Protara has scheduled an FDA meeting to define a registrational path, estimating an addressable population of about 1,000–1,200 incident patients per year and planning separate dosing, branding, and channels from the NMIBC program. IV choline chloride : Targeting chronic TPN patients (~35,000 U.S. patients), the THRIVE-1 observational data showed ~80% choline deficiency and ~68% with liver injury; Protara plans PK and liver-function endpoints and holds an Orange Book-listed patent extending to Interested in Protara Therapeutics, Inc.? Here are five stocks we like better. Protara Therapeutics (NASDAQ:TA
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics (TARA) is now covered by JPMorgan Chase & Co.. They set an "overweight" rating and a $27.00 price target on the stock.MarketBeat
- TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerGlobeNewswire
- Protara Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
TARA
Earnings
- 11/10/25 - Beat
TARA
Sec Filings
- 3/4/26 - Form 144
- 3/4/26 - Form 144
- 3/2/26 - Form SCHEDULE
- TARA's page on the SEC website